Study Shows No Causal Relationship Between COVID-19 Vaccination and Myositis

According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.

FDA Approves Expanded Label for Jascayd for PPF

Boehringer Ingelheim’s Jascayd (nerandomilast) has been given an expanded label by the U.S. Food and Drug Administration to include use in adults with progressive pulmonary fibrosis.

Lunsumio VELO Has Been Approved for R/R FL

FDA has approved CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab), as a subcutaneous formulation, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

CDC Approves Change to Nation’s Childhood Immunization Schedule

The Centers for Disease Control and Prevention has approved a change to the nation’s childhood immunization schedule to drop the long-standing practice of giving all newborns a hepatitis B vaccine within 24 hours of birth.

FDA Approves VOYXACT to Treat Kidney Disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. 

Efgartigimod Treatment Increases Spending for CIDP Patients

A new study has found that introducing efgartigimod alfa as a treatment option in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (IG) or intravenous IG would result in substantially increased spending in the treatment of CIPD.

RSV Poses Significant Threat to Patients with Systemic Autoimmune Rheumatic Diseases

A retrospective cohort study has found respiratory syncytial virus infections are associated with substantial morbidity among patients with systemic autoimmune rheumatic diseases, with more than half of infected individuals requiring hospitalization. 

FDA Approves Libtayo for Cutaneous Squamous Call Carcinoma

The U.S. Food and Drug Administration has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

Study Finds Possible Link Between Chronic Pain and Eosinophilia

A small study of medical records unexpectedly found that 12 percent of chronic pain patients who were treated with spinal cord stimulation or an implanted pain medicine pump had a white blood cell condition called eosinophilia.

Study Shows ALS May Be an Autoimmune Disorder

Researchers at La Jolla Institute for Immunology and Columbia University Irving Medical Center have discovered that amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, may be an autoimmune disorder.